Lifitegrast’s instruction manual and listing status

1. Name:Lifitegrast, Xiidra, Lifitegrast

2. Indications:

Lifitegrast 5% is indicated for the treatment of the signs and symptoms of dry eye syndrome (DED).

3. Usage and dosage:

Add one drop of Ritalast into each eye twice daily (approximately12 hours apart) using a disposable container. Discard disposable container immediately after use in each eye. Contact lenses should be removed beforeusing Ritalast and may be reinserted 15 minutes after use.

4. Adverse reactions:

In clinical studies of Litalast, common adverse reactions may include blurred vision, eye discomfort, eye irritation, or dysgeusia (an unusual or unpleasant taste in the mouth).

5. Supply and storage:

Xiidra (lifitegrast eye drops) 5% (50 mg/ml) is supplied in a foil pouch containing five 0.2 ml low-density polyethylene disposable containers and can be stored at 20°C to 25°C (68°F to 77°F). Store single-use containers in their original foil bags.

6. Taboo:

Xiidra is contraindicated in patients with known hypersensitivitylifitegrast or any other ingredient in the formula

7. Mechanism of action:

Lifitegrast binds to integrin LFA-1, a cell surface protein found on white blood cells, and blocks the interaction of LFA-1 with its cognate ligand, intercellular adhesion molecule-1 (ICAM-1). ICAM-1 may be overexpressed in corneal and conjunctival tissues in DED. The LFA-1/ICAM-1 interaction contributes to the formation of immune synapses, leading to T cell activation and migration to target tissues. In vitro studies have shown that lifitegrast can inhibit the adhesion of T cells to ICAM-1 in human T cell lines and inhibit the secretion of inflammatory cytokines in human peripheral blood mononuclear cells. The exact mechanism of action of lifitegrast in DED is unknown.

8. Listing situation

Lifitegrastand were approved by the U.S. Food and Drug Administration in July 2016, and was approved by Health Canada in January 2018.

Reference materials:https://go.drugbank.com/drugs/DB11611